Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation

Valentín Ortiz-Maldonado¹,², Gerard Frigola³, Marta Español-Rego⁴, Olga Balagué²,³, Nuria Martínez-Cibrian⁴, Laura Magnano¹,², Eva Giné¹,²,⁵, Mariona Pascal⁴, Juan G. Correa¹, Alexandra Martínez-Roca¹, Joan Cid²,⁶, Miquel Lozano²,³,⁷, Neus Villamar²,⁵,⁸, Daniel Benítez-Ribas²,⁴, Jordi Esteve¹,²,⁷,⁹, Armando López-Guillermo¹,²,⁵,⁷, Elias Campo²,³,⁵,⁷,⁸, Álvaro Urbano-Ispizua¹,²,⁷,⁹, Manel Juan²,⁴,⁷ and Julio Delgado¹,²,⁵,⁷*

¹ Department of Hematology, Hospital Clinic de Barcelona, Barcelona, Spain, ² Oncology and Hematology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³ Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁴ Department of Immunology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁵ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain, ⁶ Apheresis & Cell Therapy Unit, Department of Hemotherapy and Hemostasis, Hospital Clinic de Barcelona, Barcelona, Spain, ⁷ Department of Medicine, University of Barcelona, Barcelona, Spain, ⁸ Hematopathology Unit, Hospital Clinic de Barcelona, Barcelona, Spain, ⁹ Stem Cell Transplant and Cell Immunotherapy Group, Institute of Research Josep Carreras, Barcelona, Spain

CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.

Keywords: CLL, CART, CD19, DLBCL, Richter disease

INTRODUCTION

Patients with chronic lymphocytic leukemia (CLL) who do not respond to targeted therapies have an unfavourable prognosis, particularly if tumor cells harbour high-risk genomic aberrations (e.g. TP53 aberrations or complex karyotype) or the disease has transformed into diffuse large B-cell lymphoma (DLBCL), also known as Richter’s transformation (RT) (1). Current guidelines recommend allogeneic hematopoietic cell transplantation (alloHCT) for patients with high-risk CLL or RT (1–3). Chimeric antigen receptor T-cells targeting CD19 (CART19) are also emerging as alternative options for these patients, even though there are currently no approved products for them.
At Hospital Clinic of Barcelona, we have developed our own CART19 product (A3B1:CD8:41BB : CD3z or ARI-0001), which has been recently approved by the Spanish Medicines Agency (AEMPS) for the treatment of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) older than 25 years of age (4).

The aim of this paper is to report the outcome of all consecutive patients with CLL treated with ARI-0001 cells, either within the CART19-BE-01 trial or a subsequent compassionate use program (CUP).

METHODS

Patient Eligibility and Clinical Trial Design
ARI-0001 cells are autologous T-cells transduced with a CD137-based second generation CAR construct designed to target CD19 (5). Full details of the ARI-0001 cell development, including its structure and phenotypic characteristics can be found elsewhere (5, 6). Two patients presented here were recruited into the CART19-BE-01 study (registered as NCT03144583) (7), and the remaining patients were included in a CUP with the same inclusion criteria: (i) CD19-positive B-cell malignancy (including DLBCL or CLL); (ii) age from 2 to 80 years; (iii) ECOG performance status 0-2; (iv) estimated life expectancy from 3 months to 2 years; and (v) adequate venous access (7). Patients with CLL were eligible if they had received a minimum of 2 lines of therapy, including rituximab, and experienced disease progression within 2 years of last therapy. Key exclusion criteria included history of other malignancy unless it had been in remission for more than 3 years; severe renal, hepatic, pulmonary or cardiac impairment; active immunosuppressive therapy; HIV infection; active HBV or HCV infection; and active infection requiring systemic therapy. Of note, neither central nervous system involvement nor prior alloHCT were exclusion criteria for this trial.

Whenever feasible, patients with CLL/RT were asked to take ibritinib, at the approved dose or less in case of intolerance, for a minimum of two weeks until leukocytapheresis. Before ARI-0001 cell infusion, patients received fludarabine at 30 mg/m²/day plus cyclophosphamide at 300 mg/m²/day on days −6, −5, and −4 followed by ARI-0001 cells. The first patient received a single intravenous infusion of ARI-0001 cells, at a dose of 1 × 10⁶ cells/kg, on day 0. The remaining patients received a fractionated target dose of 1 × 10⁶ cells/kg (patients with CLL only) or 5 × 10⁶ cells/kg (patients with RT). The first fraction (10%) of ARI-0001 cells was administered on day 0, followed by the second (30%) and third (60%) fraction 24-48 hours after the first and second fraction, respectively, if the patient had no signs or symptoms of cytokine release syndrome (CRS). The implementation of the fractionated administration of ARI-0001 cells was motivated by 3 toxic deaths, all in patients with ALL (7). Intravenous immunoglobulin (IgG) replacement was recommended in case of IgG determinations lower than 4 g/L.

All patients provided written, informed consent. The AEMPS and our Institutional Review Board approved the trial, which was conducted in accordance with the principles of the Declaration of Helsinki (last updated version, Fortaleza, Brazil, 2013).

Measurement of ARI-0001 Cells and CAR19 Transgene
ARI-0001 cells presence was evaluated by flow cytometry with an APC-conjugated AffiniPure(F(ab')²)-fragment goat-anti-mouse IgG monoclonal antibody (goat-anti-mouse IgG, Jackson ImmunoResearch Laboratories). Moreover, a quantitative PCR assay was optimized and validated for monitoring ARI-0001 cell expansion and persistence. The number of transgene copies/cell was determined by quantitative real-time PCR, using Light Cycler® 480 SYBRGreen® I Master (Roche, Cat. N. 40707516001). Pairs of primers were designed against the GATA2 gene (control) and WPRE sequence (part of the transgene). Primer sequences are as follows: GATA2_F: 5’tggcgcacaactacagga 3’; GATA2_R: 5’cgagtcggaattgaagaaga 3’; WPRE_F: 5’ctcttcatacgctgcc 3’; WPRE_R: 5’cgaaggaatcagc 3’. The absolute quantification method was used to determine copy number. Standard curves were prepared using 1:10 serial dilutions of plasmids containing GATA2 or transgene. The final number of molecules in the reaction ranged from 10⁵ to 10⁷ molecules. For GATA2 quantification, GATA2 cDNA was cloned in a pCRII-Topo vector (Invitrogen). pCCL-CAR19 vector was used in the same way to quantify transgene copy number. The following PCR program was used: 1) Initial denaturation: 95°C, 5’; 2) 40 cycles of: 95°C, 10 s; 3) melting curve.

Endpoints and Statistical Analysis
The primary endpoint of the CART19-BE-01 trial was safety as determined by procedure-related mortality (PRM) and grade 3-4 toxicity at day +100 and one year. Adverse events of special interest were cytokine release syndrome (CRS), neurotoxicity [currently known as immune effector-cell associated neurotoxicity syndrome (ICANS)] and second primary malignancies. Adverse events were graded according to common terminology criteria (CTC), version 4.0. CRS was originally graded as per Lee et al. (8), but was later retrospectively reassessed using ASTCT criteria (9).

Secondary endpoints were objective response rate (ORR) and complete response rate (CRR) at day +28 and +100, duration of response (DOR), duration of B-cell aplasia (DBCA), progression-free survival (PFS) and overall survival (OS). ORR/CRR were assessed as per iwCLL (10) and Lugano (11) criteria as appropriate. Measurable residual disease (MRD) was determined in peripheral blood and bone marrow by flow cytometry, with a sensitivity of 10⁻⁴.

Adverse events and response rates are presented with 95% exact Clopper-Pearson confidence intervals. OS, PFS, DOR and DBCA, were plotted using the Kaplan-Meier method. Due to the open-label non-randomized nature of the study, the statistical analysis was descriptive and no formal comparisons between cohorts are provided. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and R (R Foundation for Statistical Computing, Vienna, Austria). The trial (EUDRA n° 2016-2972-29) was registered at clinicaltrials.gov (NCT03144583).

RESULTS
We report the outcome of nine consecutive patients with CLL treated with ARI-0001 cells, six of them with concomitant RT (Table 1). In patients with RT, tumor histology was consistent
TABLE 1

| Sex | Age | Prior therapy | Genomic aberrations | Response (iwCLL) | Outcome |
|-----|-----|---------------|---------------------|----------------|---------|
| F   | 53  | FCR, BR, I, V | 13q-                | PR             | Alive and disease-free (45.4+ months) |
| M   | 57  | BR, R-CHOP, I | 17p-, TP53 mutation | PR             | Died while disease-free (12.5 months, delayed due to COVID-19 pandemic) |
| F   | 51  | R-CHOP, RIE    | NA                 | CR             | Alive and disease-free (1.4+ months) |
| M   | 64  | R-MB, R-CHOP, I, M | t(8;22), I   | CR             | Alive and disease-free (4.2+ months) |
| F   | 47  | FCR, I, V, alloHCT | 13q-, 11q-, CK and TP53 mutation | CR             | Alive and disease-free (1.4+ months) |

Patients with concomitant RT are highlighted in grey.

Pt, patient; F, female; M, male; FCR, fludarabine, cyclophosphamide and rituximab; BR, bendamustine and rituximab; I, ibrutinib; V, venetoclax; O, obinutuzumab; IdR, idelalisib and rituximab; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine and prednisone; R-ESHAP, rituximab, etoposide, cytarabine, cisplatin and methyl-prednisolone; RIE, rituximab, etoposide and ifosfamide; Chl, chlorambucil; CHOP, cyclophosphamide, adriamycin, vincristine and prednisone; U, unmutated; I, mutated; NA, not available; CK, complex karyotype; IPI, international prognostic index (referred to diffuse large B-cell lymphoma); L, low risk; HI, high-intermediate risk; H, high risk; CRS, cytokine release syndrome; ICANS, immune effector-cell associated neurotoxicity syndrome; CR, complete response; PR, partial response.

All infused patients experienced absolute B-cell aplasia (BCA), whose median duration had not been reached (75% [95% CI: 50-100%] at 1 year, Figure 1A). Four (50%) patients had IgG determinations below 3 g/L (two of them already at screening), and five (56%) have required frequent Ig replacement. All patients had CD4+ T-cell counts below 200/µL, which recovered (>200/µL) at a median of 1.98 months after the ARI-0001 cell infusion (Figure 1B). ARI-0001 cell expansion, as measured by quantitative PCR, is displayed in Figure 2.

Seven (87.5%; 95% CI: 47-99%) patients responded according to iwCLL/Lugano criteria (CR, n = 4; PR, n = 3) (10), while one patient with RT remained with stable disease. Measurable-residual disease (MRD) was undetectable in the peripheral blood and bone marrow of all patients. With a median follow-up of 5.6 (range, 1.2-45.3) months, two patients with RT experienced a CD19-negative relapse in the lymph nodes 2.1 and 3.0 months after cell infusion (Figure 3). The 2-year OS was 62.5% (95% CI: 32-100%) from ARI-0001 cell infusion and 51.4% (95% CI: 24-100%) from inclusion in the program (this last figure includes all nine patients) (Figures 1C, D).

**DISCUSSION**

Our results were comparable to other clinical trials and small series of patients with CLL/RT treated with similar CART19...
products (12, 13), which have revealed ORRs around 38-82%, with CRRs around 20-45% (14–17). Of note, patients with RT were excluded from two pivotal trials performed in patients with DLBCL (18, 19) and, in a third trial, five patients with RT were included but their specific clinical outcome was not reported (20).

Since ibrutinib improves preclinical CART19 efficacy (21, 22), a number of clinical trials are evaluating the concomitant use of ibrutinib and CART19 cells in patients with CLL (13, 23, 24). In our experience, ARI-0001 cells could be manufactured for all patients and infused in 89% of them. A very unfortunate patient died before cell infusion, not because of excessive manufacturing time but because of the COVID-19 pandemic. Robust in vivo ARI-0001 cell expansion and persistent absolute B-cell aplasia was observed in most patients (Figures 1, 2), leading to undetectable MRD in the peripheral blood and bone marrow of all patients treated, even in those achieving a PR or stable disease in the lymph nodes. Unfortunately, two patients with RT have relapsed with CD19-negative disease despite no prior anti-CD19 therapy. This suggests that, perhaps, ARI-0001 cell therapy works better before RT occurs. However, we would still recommend ARI-0001 cell therapy for patients with RT since 3/5 patients remain in CR 1.4, 12.5 and 26.7 months after therapy.

In terms of toxicity, the fractionated administration of ARI-0001 cells appeared safe, with no cases of procedure-related mortality. The grade ≥3 CRS rate was 12.5% and there were no occurrences of ICANS. Despite the prolonged absolute B-cell
aplasia and frequent grade 4 neutropenia, the incidence of severe infections was not greater compared to similar trials (13, 15–17), and the brief exposition to ibrutinib had a minor impact on toxicity.

In conclusion, our results suggest that the administration of ARI-0001 cells is feasible, safe, and effective in patients with high-risk CLL or RT. The role of concomitant ibrutinib therapy is still debated, but we hope that ongoing and future clinical trials will help us answer this question.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Hospital Clinic de Barcelona. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

JD, MJ, ÁU-I, and JE designed the clinical trial. ME-R, MP, DB-R, and MJ were responsible for ARI-0001 cell production and monitoring after infusion. VO-M, NM-C, LM, EG, JC, AM-R, AL-G, and JD looked after the patients during the study. GF, OB and EC were responsible for pathological evaluation of lymph node biopsies. JC and ML were responsible for leukocytoapheresis. NV was responsible for immunophenotypic evaluation of peripheral blood and bone marrow samples. JD was responsible for the statistical analysis. VO-M and JD wrote the manuscript, which was approved by all authors. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

The authors would like to thank the patients who participated in the study and their families, friends, caregivers and referring physicians. The authors are very grateful to Drs. Miguel Angel Perales (Memorial Sloan Kettering Cancer Center, New York), Shannon Maude (Children’s Hospital of Philadelphia), Juan Jose Lasarte (Centro de Investigación Médica Aplicada, Navarra) and Michael Schmitt (Universitäts Klinikum Heidelberg), members

---

**FIGURE 3** | Lymph node morphology and phenotype observed in patients 5 and 6 at both study inclusion and relapse after treatment with ibrutinib-primed ARI-0001 cells. In both cases, CD19 expression was lost upon relapse.
of the CART19-BE-01 trial DSMB. The authors are also indebted to the study staff and health care providers at Hospital Clinic, specifically to Anna Boronat, Raquel Martin-Ibáñez, Unai Perpiñá, Josep M. Canals, Vanina Rodriguez, Guillermo Suñé, Esteve Trias and Jordi Yagüe who participated in the development of the CART19 construct; Sara Varea, Judit Pich, Gabriela Recalde, Leticia Pereira and Joan Albert Arnàiz, from the Clinical Trials Unit; Gonzalo Calvo, Andrea Scalise, Joaquim Sáez-Peñafati, Ferran Torres and Sandra Castaño, from the Department of Pharmacology; and Josep Maria Campistol, Antoni Castells, Aurea Mira and Marc Roda as the main representatives from the institution.

This study was funded by CatSalut, Projecte ARI and grants co-financed by the Instituto de Salud Carlos III–Subdirección General de Evaluación y Fomento de la Investigación Sanitaria–and Fondo Europeo de Desarrollo Regional (FEDER) PIC14/122, PI13/676, PIE13/33, PI18/775; and Fundació La Caixa CP042702/LCF/PR/GN18/50310007. VO-M and JD were recipients of research grants from FEHH and Generalitat de Catalunya (PERIS IPFE SLT006/17/301), respectively.

REFERENCES

1. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic Lymphocytic Leukaemia. Nat Rev Dis Primers (2017) 3:16096. doi: 10.1038/nrd.2017.8

2. Dregel P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-Risk Chronic Lymphocytic Leukemia in the Era of Pathway Inhibitors: Integrating Molecular and Cellular Therapies. Blood (2018) 132(9):892–902. doi: 10.1182/blood-2018-01-826008

3. Khafan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, et al. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Blood Blood Marrow Transplant (2016) 22(12):2317–25. doi: 10.1182/bmnt.2016.09.013

4. Juan M, Delgado J, Calvo G, Trias E, Urbano-Ispizua A. Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience With ARI-0001. Hum Gene Ther (2021) 32(19–20):1004–7. doi: 10.1089/hum.2021.168

5. Castella M, Boronat A, Martín-Ibáñez R, Rodríguez V, Suñé G, Caballero M, et al. Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Mol Ther Methods Clin Dev (2019) 12:134–44. doi: 10.1016/j.omtm.2018.11.010

6. Castella M, Caballero-Baños M, Ortiz-Maldonado V, González-Navarro EA, Suñé G, Antoñana A, et al. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-Automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Front Immunol (2020) 11:482. doi: 10.3389/fimmu.2020.00482

7. Ortiz-Maldonado V, Rives S, Castella M, Alonso-Saladiqués A, Benítez-Ribas D, Caballero-Baños M, et al. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients With CD19+ Relapsed/Refractory Malignancies. Mol Ther (2021) 29(2):636–44. doi: 10.1016/j.omtm.2020.09.027

8. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome. Blood (2014) 124(2):188–95. doi: 10.1182/blood-2014-05-552729

9. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno IN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells. Biol Blood Marrow Transplant (2019) 25(4):625–38. doi: 10.1016/j.bbmt.2018.12.758

10. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL. Blood (2018) 131 (25):2745–60. doi: 10.1182/blood-2017-09-806398

11. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zuca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol (2014) 32(27):3059–67. doi: 10.1200/JCO.2013.54.8800

12. Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, et al. Clinical Activity of Axicabtagene Ciloleucel in Adult Patients With Richter Syndrome. Blood Adv (2020) 4(19):4648–52. doi: 10.1182/bloodadvances.2020002783

13. Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and Efficacy of CD19-Targeted CAR T Cells With Concurrent Ibrutinib for CLL. ARI-0001 Cells for CLL/RT

Conflict of Interest: VO-M: Consultant or advisory role (Kite Gilead, Celgene, Novartis), travel grants (Kite Gilead, Celgene, Novartis, Roche, Takeda, Janssen), honoraria (Kite Gilead). EG: Consultant or advisory role (Kite Gilead, Janssen,
Genmab), research funding (Kite Gilead, Janssen, Roche). AM-R: Consultant or advisory role (Bristol Myers Squibb, Abbvie), travel grants (Kite Gilead, Roche, Takeda, Janssen, Abbvie), honoraria (Abbvie). ML: Honoraria (Grifols, Fresenius Kabi), research funding (Terumo BCT, Maco-Pharma). JE: Consultant or advisory role (Abbvie, Novartis, Celgene, Astellas, Jazz, Daiichi Dankyo, Roche, Amgen, Pfizer), travel grants (Celgene, Roche, Astellas, Daiichi Dankyo), research funding (Novartis, Celgene). AL-G: Consultant or advisory role (Roche, Kite Gilead, Celgene/Bristol-Myers, Incyte), honoraria (Roche, Novartis, Takeda, Bayer, Sandoz, Kern), research grants (Roche, Kite Gilead, Celgene/Bristol-Myers, Novartis, Incyte, Janssen, Pfizer, Takeda). AU-I: Consultant or advisory role (Kite Gilead, Celgene, Miltenyi), travel grants (Kite Gilead, Celgene). MJ: Consultant or advisory role (Kite Gilead, Grifols), honoraria (Kite Gilead, Grifols).

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ortiz-Maldonado, Frigola, Español-Rego, Balagué, Martínez-Gibrán, Magnano, Gine, Pascal, Correa, Martínez-Roca, Cid, Lozano, Villamar, Benítez-Ribas, Esteve, López-Guillermo, Campo, Urbano-Ispizua, Juan and Delgado. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.